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Abstract: Omega-3 fatty acids (n-3 FA) may have beneficial clinical and immune-modulating 
effects in surgical patients. In a randomized, double-blind, prospective, placebo-controlled 
trial, 148 patients referred for elective colorectal cancer surgery received an n-3  
FA-enriched oral nutritional supplement (ONS) providing 2.0 g of eicosapentaenoic acid 
(EPA) and 1.0 g of docosahexaenoic acid (DHA) per day or a standard ONS for seven days 
before surgery. On the day of operation, there was a significant increase in the production of 
leukotriene B5 (LTB5) (p < 0.01) and 5-hydroxyeicosapentaenoic acid (5-HEPE) (p < 0.01), 
a significant decrease in the production of leukotriene B4 (LTB4) (p < 0.01) and a trend for a 
decrease in the production of 5-hydroxyeicosatetraenoic acid (5-HETE) (p < 0.1) from 
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stimulated neutrophils in the active group compared with controls. There was no association 
between LTB4 values and postoperative complications. In conclusion, oral n-3 FA  
exerts anti-inflammatory effects in surgical patients, without reducing the risk of 
postoperative complications. 
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1. Introduction 
Patients undergoing surgery are at risk of developing complications in the postoperative period [1–3]. 
This is believed to be partly caused by changes in the immune response following surgery [4]. Thus, 
initially, a hyper-inflammatory response followed by a phase of relative immune incompetence occurs 
in relation to major surgery [5]. 
The pathophysiological changes are complex, but may be driven by excessive production of various 
lipid mediators, including the very potent pro-inflammatory leukotriene B4 (LTB4) produced from the 
omega-6 fatty acid (n-6 FA) arachidonic acid (AA) present in cell membranes.  
Among factors known to influence the clinical course of patients after surgery are nutritional status 
and specific biologically active nutrients [2,6–10] that might include the marine omega-3 fatty acids  
(n-3 FA) with the main biologically active n-3 FAs being eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). Consumption of fish and fish oils oil increases the concentration of EPA 
and DHA in blood, cells and tissues [11,12] and alters the physical properties of cell membranes and the 
function of membrane proteins, including receptors, transporters and signalling proteins [13,14].  
n-3 FA are incorporated into cell membranes in competition with the more abundant n-6 FA, AA, at the 
expense of the latter. AA may be liberated by phospholipases from cell membranes and induces 
leucocytes to produce the pro-inflammatory LTB4 and the side product, 5-hydroxyeicosatetraenoic acid 
(5-HETE). In contrast, leukotriene B5 (LTB5) and the side product, 5-hydroxyeicosapentaenoic acid  
(5-HEPE), derived from EPA [15], have considerably less potent biological activities in comparison to 
LTB4 [15,16]. Replacement of n-6 FA with n-3 FA in membranes of immune active cells may therefore 
lead to reduced formation of pro-inflammatory compounds, and by this, and other [5,12] mechanisms, 
n-3 FA may decrease infectious complications after surgery [7,17–20]. The influence of enteral feeds, 
including n-3 FA on AA-derived eicosanoids (e.g., LTB4), has been the subject of much attention [5,21–23]. 
Several studies have indicated that n-3 FAs modulate the generation of inflammatory eicosanoids in 
gastrointestinal surgical patients [24–26] and may help to counteract the surgery-induced decline in 
antigen-presenting cell activity [20] and T-cell cytokine production [27]. 
The aim of the present study was to evaluate the production of LTB4, 5-HETE, LTB5 and 5-HEPE 
from stimulated neutrophils after seven days of preoperative treatment with an n-3 FA-enriched oral 
nutritional supplement (ONS) in patients undergoing colorectal cancer surgery and to study the possible 
impact on clinical outcome. Furthermore, the correlation between LTB4 values and postoperative 
complications was investigated. 
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2. Materials and Methods 
2.1. Study Design 
This was a sub-study of a randomized, double-blind, prospective, placebo-controlled single-centre 
interventional trial involving 148 participants (Figure 1) awaiting colorectal cancer surgery [28]. 
Participants were recruited consecutively from the outpatient clinic of the Department of Surgical 
Gastroenterology, Aalborg University Hospital. All eligible participants were asked to participate. 
Exclusion criteria were diabetes mellitus, consumption of >5 alcoholic drinks per day, emergency 
surgery, inability to understand the spoken and written information in Danish, untreated psychiatric 
conditions, pregnancy or breast-feeding, reduced kidney function (plasma creatinine > 130 μmol/L), use 
of n-3 FA supplements, anticipated poor compliance, immunosuppressive diseases and participation in 
another clinical trial. 
After providing oral and written informed consent, participants were randomly assigned to treatment 
with n-3 FA (active treatment) or control (a standard ONS without marine n-3 FA), 200 mL twice per 
day (morning and afternoon) for 7 days before surgery. Randomization was performed using sealed  
non-transparent envelopes containing the randomization number and kept at the investigation site 
according to CONSORT (Consolidated Standards of Reporting Trials) guidelines [29]. The active and 
the control ONS cartons looked identical and had identical taste and scent (coffee). The main investigator 
and a study nurse enrolled the participants at the outpatient clinic and randomly assigned them to active 
treatment or control. The participants, carers, investigators and other researchers were blinded to 
treatment allocation throughout the study. The investigators had no access to the code until after 
completion of the study. Statistical analyses were completed before the code was broken. 
Information collected included demographic data, tumour location and American Society of 
Anaesthesiologists (ASA) risk score [30]. All patients underwent standard Nutritional Risk Screening 
(NRS 2002) [31]. A food questionnaire focusing on consumption of seafood on a monthly basis was 
completed at baseline.  
The study was approved by the regional ethics committee (N-VN-20050035) and conducted 
according to the Hong Kong amendment to the Declaration of Helsinki. The trial was registered at 
ClinicalTrials.gov: ID NCT00488904 [32]. 
2.2. Intervention 
Participants in the active or control group received the ONS as a sip feed (200 mL twice a day morning 
and afternoon) for 7 days before surgery. The feeds (Supportan®) were isocaloric (1.5 kcal/mL) and 
isonitrogenous (Table 1) and were provided by Fresenius Kabi (Bad Homburg, Germany). Both feeds 
contained the same amounts of carbohydrate, protein, total fat and n-6 FA (Table 1). 
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Figure 1. Patient flow through the study. 
 
Table 1. Daily intake of energy and nutrients from the n-3 FA-enriched and the control oral 
nutritional supplement. 
Daily dose Control n-3 FA (Active) 
Energy (kcal) 600 600 
Protein (g)  40 40 
Carbohydrate (g) 49.6 49.6 
Fat (g) 26.8 26.8 
EPA (g) 0 2 
DHA (g) 0 1 
Total n-6 FA (g) 3.3 3.3 
Analysed (n = 65) 
 Excluded from analysis (n = 0) 
Lost to follow-up (n = 0) 
Allocated to intervention with omega-3 
FA (n = 74) 
 Received allocated intervention n  
(n = 65)  
 Did not receive allocated intervention  
(n = 9) 
Could not drink the sip feed (n = 1) 
Logistics (n = 2) 
Postoperative mortality (n = 2) 
   No operation (n = 1) 
   Patient refusal (n=3) 
 
 
 
 
 
 
 
 
 
 
 
  
Lost to follow-up (n = 0) 
 
Allocated to intervention with control  
(n = 74) 
 Received allocated intervention  
(n = 64) 
 Did not receive allocated intervention 
(n = 10) 
Logistics (n = 2) 
Postoperative mortality (n = 2) 
No operation (n = 2) 
   Patient refusal (n=4) 
 
 
 
 
 
 
 
 
 
Analysed (n = 64) 
 Excluded from analysis (n = 0) 
 
Allocation 
Analyses 
Follow-Up 
Randomized (n = 148) 
Assessed for eligibility 
(n=610) 
Excluded (n = 462) 
 Not meeting inclusion criteria (n = 201) 
 Declined to participate (n = 31) 
 Logistic reasons (n = 230) 
Enrollment 
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Fat content of the supplement was comprised of medium chain triglycerides, sunflower oil and 
safflower oil. The active supplement also contained additional fish oil at a level to achieve 2 g EPA and 
1 g DHA per day (Table 1). Participants were provided with the sip feeds at inclusion, to consume twice 
a day for 7 days at home before hospitalization. A questionnaire regarding compliance preoperatively 
was completed, and good compliance was defined as self-reported consumption of at least 12 of the 14 
ONS cartons before surgery. 
2.3. Isolation of Blood Neutrophils 
Blood was drawn in the fasting state on the day of the surgery. Neutrophils were separated from 
anticoagulated (K-EDTA 1.6 mg/mL) blood layered on top of PolymorphprepTM (AXIS-SHIELD PoC 
AS, Rodeloekka, Norway) and separated by a one-step centrifugation technique at 450 g for 40 min. 
Neutrophils were harvested and washed twice in tissue culture medium (RPMI 1640, Sigma-Aldrich, 
Ayrshire, UK), at ambient temperature and centrifuged for 10 min at 520× g. Subsequently, neutrophils 
were counted and red cells eliminated by the addition of ice-cold 0.2% saline for 35 s. Next, 1.6%  
ice-cold saline was added in order to obtain an isotonic 0.9% concentration, followed by centrifugation 
at 300× g at 5 °C for 5 min, which was repeated once. Neutrophils were then washed in a phosphate 
buffer containing glucose and human albumin (PBS) and resuspended in PBS adjusting the concentration 
to 1 × 107 neutrophils/mL PBS. Isolated neutrophils were stored at −80 °C until analysis. 
2.4. Analysis of Leukotrienes, 5-HEPE and 5-HETE 
The neutrophil suspension (0.9 mL of 1 × 107 granulocytes/mL PBS) was prewarmed to 37 °C, and 
CaCl2, MgCl2 and calcium ionophore (A23187) at a final concentration of 10 µM were added to initiate 
stimulation. After 10 min, the reaction was terminated by the addition of 100% ice-cold ethanol, and the 
mixtures were centrifuged at 4 °C at 700× g. The supernatant was stored at −80 °C for later analysis. 
C18 cartridges (Sep-Pak VAC RC, Waters Co., Milford, MA, USA) were used for the extraction of 
leukotrienes (LT), 5-HEPE and 5-HETE. The ethanol mixture was thawed and centrifuged, and 
international standard prostaglandin B2 (PGB2) and trifluoroacetic acid were added. The cartridges were 
conditioned and equilibrated using methyl formate, 100% ethanol and water. The acidified sample was 
loaded onto the cartridge, washed with 15% ethanol, water and hexane and eluted with methyl formate. 
The solvent was evaporated to dryness under nitrogen, and the sediment was dissolved in the mobile 
phase (31% H2O, 27% methanol, 42% acetonitrile and 0.025% trifluoroacetic acid). 
Analysis was performed by high pressure liquid chromatography (Dionex Ultimate LPG-3400A) on 
an Acclaim RSLC 2.1 mm × 100 mm C18 column (Dionex Corporation, Sunnyvale, CA, USA). 
Concentrations were calculated using the internal standard and response factors. The response factors 
were calculated by analysis of a non-stimulated neutrophil suspension after the addition of known 
amounts of standards of LTB4, LTB5, 5-HETE and 5-HEPE, as well as an internal standard (PGB2). 
Samples were extracted and analysed using high performance liquid chromatography, and eventually, 
the recovery factors were calculated. 
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2.5. Granulocyte Fatty Acid Analysis 
Blood was drawn in the fasting state on the day of surgery. Granulocytes were prepared as described 
previously [33]. FA profiles were determined by gas chromatography using a Varian 3900 gas 
chromatograph, CP-8400 autosampler and CP 8414 autoinjector (Varian, Middelburg, The Netherlands), 
as well as a flame ionization detector. In split injection mode, a CP-sil 88.60-m × 0.25-mm capillary 
column (Varian, Middelburg, The Netherlands), temperature programming from 90 to 205 °C, a constant 
flow rate of 1.0 mL/min and helium carrier gas were used. Results for individual FAs are expressed as 
a percentage of the total FA content. 
2.6. Statistical Analysis 
The basic characteristics of the trial population were analysed with Fisher’s exact test for categorical 
variables and unpaired t-tests for continuous variables. Differences between treatment groups were 
analysed using unpaired t-tests. If variances differed between groups, Welch’s approximation was used. 
The distribution of continuous data was analysed for normality. As the values for 5-HEPE, 5-HETE and 
LTs were right skewed distributed, log transformed observations were analysed, and these were normally 
distributed. Distributions of 5-HEPE, 5-HETE and LT were described with median and inter-quartile 
range (IQR). Relative differences between groups in medians were calculated by exponentiation of the 
differences between log-transformed means. Associations between LTB4 values and postoperative 
complications were analysed using logistic regression. The associations between log-transformed LT 
values 5-HEPE and AA, EPA and AA/EPA were analysed using linear regression. Analyses were 
performed blinded to treatment groups. The active and control groups were not identified until after the 
statistical analyses had been conducted. All p-values were two-tailed, and differences were reported with 
95% confidence intervals (CI). p-values below 0.05 were considered significant. All analyses were 
performed using Stata version 11.2 (StataCorp, 2009; Texas City, TX, USA). 
3. Results 
3.1. Participants Characteristics 
All eligible participants (n = 610) were asked to participate, but 230 participants were not included. 
This was due to a change in clinical practice during the study, such that many patients were offered 
surgery within a five-day period, which did not allow for participants to complete the seven-day 
intervention. Furthermore, some participants did not meet the inclusion criteria (201), and 31 participants 
declined to participate. Baseline characteristics of the included vs. the non-included participants did  
not differ. 
A total of 148 consecutive patients (68 females, 80 males; mean age 71 (range 41–89) years) were 
included in the study. The majority of participants had open surgery; laparoscopic resection was only 
performed in nine patients in the control group and nine in the n-3 FA group. Participant characteristics 
did not differ between treatment groups (Table 2). 
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Table 2. Characteristics of patients in the control and active groups. 
Variable Control (n = 74) Active (n = 74) p 
Demographic data    
Age, years, mean (SD) 71 (10) 69 (11) 0.164 
Sex (male/female) 36/38 44/30 0.248 
Body weight, kg, mean (SD) 76 (19) 77(17) 0.570 
Height, cm, mean (SD) 169 (11) 171 (9) 0.301 
BMI, kg/m2, mean (SD) 26 (5) 26 (5) 0.651 
Weight loss * (n) 19 11 0.068 
Clinical characteristics    
Smoking/non-smoking (n) 11/60 17/54 0.292 
Unknown smoking status 3 3  
Cancer location    
Colon/rectum (n) 40/34 38/36 0.869 
Surgical procedure   0.977 
Right hemicolectomy + transverse colon (n) 16 17  
Left hemicolectomy + sigmoid colon (n) 10 12  
Laparoscopic resection of sigmoid colon (n) 9 9  
Low anterior resection of rectum or  
abdominoperineal resection 
28 30  
Colectomy (n) 4 3  
Other rectum resection (n) 7 3  
Nutritional status **   0.089 
No risk (NRS score <3) (n) 23 34  
At risk (NRS score ≥3) (n) 50 39  
Unknown (n) 1 1  
Notes: There were no significant differences between groups (p > 0.068); BMI, body mass index; * defined as loss of more 
than 5% of body weight; ** defined according to NRS 2002 [31]. 
3.2. Fatty Acid Composition of Neutrophils 
Neutrophil EPA and DHA were significantly higher, and AA and linoleic acid was significantly lower 
in the group receiving n-3 FA than in the control group (Table 3) [28].  
The food questionnaire indicated an average dietary intake of n-3 FA of 0.6 g per day, with no 
difference in preoperative intake between groups (p = 0.770). None of the included participants received 
more than 150 mg of anti-inflammatory drugs daily. Both supplements were well tolerated with no 
adverse effects reported. Nine participants randomized to active treatment and 10 participants in the 
control group did not receive the allocated intervention for reasons listed in Figure 1. 
Preoperatively, 63 of 65 participants in the active group were compliant compared with 56 of  
64 participants in the control group (p = 0.266). Two participants died in each group. In the active group, 
death was caused by pneumonia and a myocardial infarction, whereas the participants in the control 
group died from septicaemia and sudden cardiac death. 
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Table 3. Granulocyte fatty acids on day of operation in the control and active groups. 
 Weight% of Total FA Content  
Control Active 
EPA 0.54 (0.42–0.74) 2.10 (1.83–2.55) * 
DPA 0.54 (0.42–0.74) 2.11 (1.83–2.55) * 
DHA 1.31 (1.10–1.57) 1.61 (1.34–1.84) * 
Total n-3 FA 2.44 (1.98–2.97) 5.95 (5.20–6.75) * 
Arachidonic acid 12.51 (11.65–13.19) 11.61 (10.67–12.48) * 
Linoleic acid 8.94 (8.24–9.49) 9.42 (8.72–10.19) ** 
Notes: Values are the median (IQR); FA, fatty acid; ONS, oral nutritional supplement; EPA, eicosapentaenoic 
acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; * p < 0.001; ** p < 0.05 versus the  
control group. 
3.3. Production of Mediators from Neutrophils 
Furthermore, compared to neutrophils from controls, those from participants in the n-3 FA group 
showed a significantly higher (by 176% and 306%, respectively) production of LTB5 (p < 0.001) and  
5-HEPE (p < 0.001) (Table 4). 
Table 4. Formation of leukotrienes (LT) and side products (5-HEPE; 5-HETE) from 
activated neutrophils according to treatment group. 
Eicosanoids Control Active % Difference 
LTB5 5.8 (4.9–7.6) 17.5 (13.5–22.8) 176 *** (143–215) 
LTB4  186.8 (156.8–230.7) 163.5 (136.6–199.9) −12 *** (−21–−3) 
5-HETE  293.1 (246.5–357.8) 273.7 (221.8–320.7) −7 * (−14–−0) 
5-HEPE  34.2 (25.7–55.3) 154.7 (122.4–190.4) 306 *** (255–364) 
LTB4/LTB5 31.8 (25.0–40.1) 9.6 (7.8–11.4) −68*** (−72–−65) 
Notes: Data are the median (IQR) ng/107 neutrophils and the percentage of difference between estimated 
medians; *** indicates p < 0.01; * indicates p < 0.1; ng/107 = nanogram/107 neutrophils. 
Conversely, in the active group, neutrophils showed a significantly lower (by 12%) production of 
LTB4 (p < 0.001) and a trend towards lower (by 7%) production of 5-HETE (p = 0.059). LTB4/LTB5 
was significantly different between groups (by 68%) (p < 0.001) (Table 4). There was no statistically 
significant difference in clinical outcomes (total number of complications, infectious complications, 
non-infectious complications, intensive care unit stay, mortality, readmissions and hospital stay) 
between groups, as reported previously [28]. 
There was no statistically significant association between the values of the proinflammatory LTB4 
production and any clinical outcome, including total number of complications (p = 0.524), infectious 
complications (p = 0.660) and non-infectious complications (p = 0.307) (Table 5). The ratio LTB4/LTB5 
did not have a statistically significant association with the total number of complications (p = 0.707), 
infectious complications (p = 0.711) and non-infectious complications (p = 0.143) (Table 4). 
However, There were strong associations between the content of AA and EPA in neutrophils and 
production of LTB4 and LTB5 (Figure 2) (all p < 0.01). 
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These graphs illustrate that the higher the content of EPA in the cell membranes, the higher the 
production of LTB5. Furthermore, it can be seen that the higher the content of AA in cell membranes, 
the lower the production of LTB5. Furthermore, there were strong associations between AA/EPA in 
neutrophils and LTB4 and LTB5 production (both p < 0.01) (results not shown) and between AA, EPA, 
AA/EPA and 5-HEPE production (all p < 0.001) (results not shown). 
Figure 2. Associations between log-transformed AAg (AA content in the cell membranes of 
the granulocytes) and EPAg (EPA content in the cell membranes of the granulocytes) in the 
neutrophils, as well as the formation of LTs (LTB4 and LTB5 (ng/107)) by neutrophils, 
illustrated using scatter plots with regression lines and confidence bands added. Control 
group, red dots; active group, blue dots. 
 
Table 5. Associations between LTs production by neutrophils and clinical outcome 
described by odds ratio (OR), CI and p-values for a unit change in LTB4 and  
LTB4/LTB5, respectively. 
 LTB4 LTB4/LTB5 
OR CI p OR CI p 
Infectious complications 1.00 1.00–1.01 0.660 1.00 0.97–1.03 0.711 
Non-infectious complications 1.00 0.99–1.00 0.307 0.98 0.94–1.00 0.143 
Total number of complications 1.00 0.99–1.00 0.524 1.00 0.98–1.03 0.707 
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4. Discussion 
In this prospective randomized, double-blind, single-centre, placebo controlled study, it was 
demonstrated that seven days of enteral supplementation with 3 g of EPA + DHA daily resulted in a 
higher neutrophil production of LTB5 and a lower production of LTB4 compared to the control group. In 
addition, there was a higher neutrophil 5-HEPE production and a trend to lower production of  
5-HETE in the active group compared to the control. While the differences in LTB4 and LTB5 production 
indicate an anti-inflammatory action of the supplement, it is unknown whether the difference in 
formation of 5-HETE and 5-HEPE between groups is of clinical relevance. However, 5-HETE enhances 
lymphocyte proliferation, whereas 5-HEPE only has one-tenth the potency of 5-HETE regarding  
this [34]. Thus, the current study demonstrates that preoperative supplementation with n-3 FA for one 
week can modulate immune function, assessed as the production of lipoxygenase mediators, in 
participants admitted for elective colorectal cancer surgery. However, this was not associated with a 
decrease in postoperative complication rates [28]. 
The strengths of the present study are that it was a randomized, prospective, relatively large clinical 
study, was double-blind, with an identical appearance for the sip feed cartons, the taste of n-3 FA  
was undetectable and that compliance was acceptable. Furthermore, the study population was  
relatively homogenous. 
One limitation of the present study is that we only had data on eicosanoid formation from the day of 
surgery, whereas postoperative changes would also have been of interest. The short duration of the 
intervention (seven days) may have limited the incorporation of n-3 FA and the decrease of AA in 
neutrophils and, thereby, limited the impact on LTB4 production, but a longer period of supplementation 
was not possible, as participants were operated on soon after cancer diagnosis. However, we showed in 
earlier publications that 3 g of n-3 FA for seven days before surgery was sufficient to assure significant 
incorporation of n-3 FA into neutrophils and into colonic tissue [28,35]. The required sample size was 
based on a reduction in postoperative infection rates from 30% to 10% and was calculated to be 148 
participants in all, but we were only able to analyse data from 129 of these. A final limitation is the 
discrepancy between the number of eligible (610) and analysed participants (129) due to a change in 
clinical practice during the study, such that many patients were offered surgery within a five-day period, 
which did not allow for participants to complete the seven-day intervention. 
Our findings are consistent with the results from three recent studies in humans [24,36,37]. In a 
prospective double-blind study, Wang et al. [37] randomized 64 participants with a need for 
postoperative parenteral nutrition after surgery into two groups. The study population was a mix of 
surgical patients (22 gastric cancers; 29 colonic cancers; 13 with other digestive diseases). They received 
either fish oil containing lipid emulsion (a mixture of soybean oil, MCT and fish oil) as part of the 
intravenous regimen, or a mix of soybean oil and MCT for 5 days after surgery. There was a significant 
increase in the neutrophil LTB5/LTB4 ratio but no effect on clinical outcome, infectious complications 
and bleeding events. Grimm et al. [36] randomized 33 participants undergoing major abdominal surgery 
into two groups in a prospective double-blind study to receive parenteral nutrition providing either a fish 
oil containing lipid emulsion (a mixture of soybean oil, MCT, olive oil and fish oil) or soybean oil for 
five days after surgery. The study population was again a mix of surgical patients. The initial production 
of LTB4 and LTB5 by neutrophils was similar in both groups. The production of LTB5 from neutrophils 
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was significantly increased, and the release of LTB4 was decreased, though not significantly, in the 
participants receiving fish oil. The length of hospital stay was significantly shorter in the intervention 
group. Finally, Köller et al. [24] conducted a prospective double-blind randomized study with 30 
participants undergoing colorectal surgery. Participants received parenteral nutrition, providing either a 
fish oil containing lipid emulsion (a mixture of soybean oil, MCT and fish oil) or soybean oil for five 
days post-surgery. This study also found a significant increase in LTB5 production by leukocytes in the 
fish oil group, but without a concomitant decrease in LTB4 production. These three studies all made use 
of intravenous (IV) nutrition given postoperatively. The present study, which used enteral nutrition given 
preoperatively, agrees with these earlier findings of increased LTB5 production and decreased LTB4 
production after fish oil provision, but with limited clinical impact. 
Some earlier studies have reported beneficial effects of oral n-3 FA supplementation in 
gastrointestinal surgery patients. Wachtler et al. [26] analysed leukocyte function in 40 participants 
undergoing major upper gastrointestinal surgery in a placebo-controlled double-blind study. One group 
received an n-3 FA-enriched (0.33 g/100 mL) oral supplement, also containing arginine and ribonucleic 
acid, and the other group received a standard control supplement for five days preoperatively. There was 
a significantly higher production of LTB5 from neutrophils in the intervention group when compared to 
controls. However, no changes in LTB4 were evident in the intervention group. The authors reported a 
low number of postoperative complications. In another study, Shimizu et al. [38] gave 12 children with 
ulcerative colitis 1.8 g EPA orally per day for two months. LTB4 production by leucocytes and colonic 
mucosa were assessed before and after the intervention. Biopsies were taken from the rectal mucosa 
during sigmoidoscopy before and after initiation of EPA supplementation. After two months of 
supplementation, there was a decrease in LTB4 production by leucocytes and colonic mucosa, while no 
information regarding LTB5 production was given. 
IV administration of n-3 FA ensures a quicker incorporation of the presumed active substances (n-3 
FA) into the membranes of immune cells [39,40]. However, this format is not feasible in the  
pre-operative setting. ONSs are less expensive and enable the use of the gut prior to surgery. Two studies 
providing IV n-3 FA for five days post-operatively did not show any decrease in the production of  
LTB4 [24,36]. Importantly many of these studies did not provide explicit information about the amount 
of n-3 FA given.  
In the present study, seven days of oral supplementation with 3 g of n-3 FA daily ensured significant 
incorporation of EPA into neutrophils and a significant decrease in the formation of LTB4. However, to 
achieve an anti-inflammatory response meditated by n-3 FA, it is probably more important that the 
formation of the AA-derived LTB4 is suppressed than an increase in LTB5. Despite this, there was no 
effect on clinical outcome in the current study. One explanation for this may be that n-3 FA incorporation 
was not sufficiently high. A higher n-3 FA dose or a longer duration of intervention could have had an 
impact on clinical outcome. The ratio LTB4/LTB5 was 68% lower in the active group, which is a 
considerable decrease, but still did not have any effect on clinical outcome.  
One other important factor may be that the nutritional status of the patients, evaluated by NRS 2002, 
was generally good for most participants. A weight loss of more than 5% of body weight was only 
detected in 23% of participants entering the study. This could account for the lack of clinical 
improvement with the n-3 FA-enriched ONS, since it is likely that malnourished participants might 
benefit the most from ONS and from oral n-3 FA. 
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5. Conclusions 
In summary, the current study shows that an ONS providing 3 g of n-3 FA daily for seven days before 
surgery was able to induce a significant decrease in the formation of the pro-inflammatory LTB4 from 
neutrophils with a simultaneous increased production of LTB5. A decrease in the formation of 5-HETE, 
though not significant, and a significant rise in 5-HEPE was also seen. However, the clinical 
consequences of these changes are unknown. Associations between values of LTB4 or LTB4/LTB5 and 
postoperative complication rates were not seen. This indicates either that the changes observed were too 
small or that the formation of LTs from activated neutrophils is not an important determinant of surgical 
complications. Whether a longer period (months) of n-3 FA intake could be of a benefit for patients 
operated on for colorectal cancer regarding shorter stay in hospital or longer survival needs to be 
investigated in larger trials. 
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